Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Adenocarcinoma of Lung
/ drug therapy
Antineoplastic Agents, Immunological
/ therapeutic use
Biomarkers, Tumor
/ analysis
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Female
Follow-Up Studies
Gastrointestinal Microbiome
Humans
Immunotherapy
/ mortality
Lung Neoplasms
/ drug therapy
Male
Metabolome
Middle Aged
Prognosis
Prospective Studies
Survival Rate
intestinal flora
non-small cell lung cancer
programmed cell death 1 (PD-1)
programmed cell death 1 ligand(PD-L1)
Β-diversity
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
14
03
2020
revised:
31
03
2020
accepted:
01
04
2020
pubmed:
25
4
2020
medline:
16
3
2021
entrez:
25
4
2020
Statut:
ppublish
Résumé
Many immune checkpoint inhibitors (ICIs) have been approved in China to treat non-small cell lung cancer (NSCLC). However, in the long term, less than 20% of patients benefit from ICIs. To maximize the benefit for NSCLC patients, it is necessary to guide the choice of immunotherapy through biomarkers. Recent studies have shown that gut microbiota can affect tumor response to immunotherapy and might be a potential predictive biomarker. This study analyzed the relationship between intestinal flora structure and metabolomic characteristics in NSCLC and the efficacy of ICIs. Prospective analysis of samples from 63 patients with advanced NSCLC who attended the Department of Respiratory Medicine of the Peking Union Medical College Hospital from March 2018 to June 2019, and were prescribed programmed cell death 1 (PD-1) inhibitors, was carried out. The follow-up deadline was 31 December 2019. Stool samples were collected from all patients before the start of immunotherapy. DNA was extracted from all samples and libraries were constructed. This was followed by sequencing using the Illumina sequencing platform, and results were studied using a biological information data analysis process. We divided the data into two groups based on progression-free survival (PFS) ≥ six months and PFS < six months. The median PFS was 7.0 months, not reaching the median overall survival (OS). We obtained 373.5 G of original sequencing data. The phyla Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria accounted for most of the bacterial communities in the stool samples studied. Compared with the PFS < six-month group, the patients in the PFS ≥ six-month group had significantly higher β-diversity in the intestinal microbiome at the baseline level. There were also differences in composition between the two groups. Samples in the PFS ≥ six-month group were rich in Parabacteroides and Methanobrevibacter, while those in the PFS < six-month group were rich in Veillonella, Selenomonadales, and Negativicutes. The KO, COG, and CAZy databases were used to study functional group protein families, yielding 390 (KO), 264 (COG), and 859 (CAZy) functional group abundances, with significant differences between the two groups. Bacterial metabolites analysis suggested significant differences in the metabolic potential of methanol and methane between the two groups. We found a close correlation between intestinal microbiome β-diversity and anti-PD-1 immunotherapy response in Chinese patients with advanced NSCLC. The intestinal flora composition, functional group protein family, and KEGG metabolism also differed between the two groups. Differences in pathways and flora metabolites were also noted.
Sections du résumé
BACKGROUND
Many immune checkpoint inhibitors (ICIs) have been approved in China to treat non-small cell lung cancer (NSCLC). However, in the long term, less than 20% of patients benefit from ICIs. To maximize the benefit for NSCLC patients, it is necessary to guide the choice of immunotherapy through biomarkers. Recent studies have shown that gut microbiota can affect tumor response to immunotherapy and might be a potential predictive biomarker. This study analyzed the relationship between intestinal flora structure and metabolomic characteristics in NSCLC and the efficacy of ICIs.
METHODS
Prospective analysis of samples from 63 patients with advanced NSCLC who attended the Department of Respiratory Medicine of the Peking Union Medical College Hospital from March 2018 to June 2019, and were prescribed programmed cell death 1 (PD-1) inhibitors, was carried out. The follow-up deadline was 31 December 2019. Stool samples were collected from all patients before the start of immunotherapy. DNA was extracted from all samples and libraries were constructed. This was followed by sequencing using the Illumina sequencing platform, and results were studied using a biological information data analysis process. We divided the data into two groups based on progression-free survival (PFS) ≥ six months and PFS < six months.
RESULTS
The median PFS was 7.0 months, not reaching the median overall survival (OS). We obtained 373.5 G of original sequencing data. The phyla Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria accounted for most of the bacterial communities in the stool samples studied. Compared with the PFS < six-month group, the patients in the PFS ≥ six-month group had significantly higher β-diversity in the intestinal microbiome at the baseline level. There were also differences in composition between the two groups. Samples in the PFS ≥ six-month group were rich in Parabacteroides and Methanobrevibacter, while those in the PFS < six-month group were rich in Veillonella, Selenomonadales, and Negativicutes. The KO, COG, and CAZy databases were used to study functional group protein families, yielding 390 (KO), 264 (COG), and 859 (CAZy) functional group abundances, with significant differences between the two groups. Bacterial metabolites analysis suggested significant differences in the metabolic potential of methanol and methane between the two groups.
CONCLUSIONS
We found a close correlation between intestinal microbiome β-diversity and anti-PD-1 immunotherapy response in Chinese patients with advanced NSCLC. The intestinal flora composition, functional group protein family, and KEGG metabolism also differed between the two groups. Differences in pathways and flora metabolites were also noted.
Identifiants
pubmed: 32329229
doi: 10.1111/1759-7714.13442
pmc: PMC7262920
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1621-1632Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Nutr Rev. 2011 Jul;69(7):392-403
pubmed: 21729093
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Front Microbiol. 2017 Jun 23;8:1162
pubmed: 28690602
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Nature. 2016 Jul 06;535(7610):94-103
pubmed: 27383984
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Nat Med. 2018 Oct;24(10):1532-1535
pubmed: 30150716
Nature. 2016 Jun 08;534(7606):191-9
pubmed: 27279212
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Microbiome. 2017 Jul 7;5(1):71
pubmed: 28683818
Cell Rep. 2019 Jan 2;26(1):222-235.e5
pubmed: 30605678
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Nat Commun. 2016 Aug 03;7:12431
pubmed: 27485204
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Science. 2016 Apr 29;352(6285):560-4
pubmed: 27126039
J Thorac Oncol. 2019 Aug;14(8):1378-1389
pubmed: 31026576